Avivagen Creating New Technology

Canadian life sciences company, Avivagen, claims to be developing two disruptive technologies. The first is a natural product designed to replace antibiotic use in livestock feeds and the second is a medication-based non-surgical sterilization process for female animals.

Avivagen is currently using its antibiotic replacement (OxC-beta) in two pet supplements (Vivamune and Oximunol) and is looking to expand its use in livestock destined for consumption.

About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol “VIV” and on OTC Pink as “CHEXF.” The Company’s goal is to develop and deliver scientifically-proven solutions that benefit companion and production animals by employing natural mechanisms for maintaining good health. Target markets include Livestock Productivity and Pet Wellness.

Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) – in Ottawa, Ontario and Charlottetown, Prince Edward Island.

READ THE FULL ARTICLE       

Avivagen Appoints Two New Board of Directors

On May 14th Avivagen announced the appointment of two new board of directors; David Allan and Vanessa Grant. Two previous directors have resigned, Dr. Janusz Daroszewski and Dr. Chandra Panchal. The appointments of Allan and Grant remain subject to TSX Venture Exchange approvals.

Allan was the Chairman and CEO of YM BioSciences Inc. from 1998 to 2010. He was the founding Chairman of AvidBiologics, the Executive Chairman of Stem Cell Therapeutics Corp., and the Lead Director of DiaMedica Inc. Allan has also been a CEO or senior executive of three Canadian investment dealers and a Governor of the Toronto Stock Exchange. Regarding his appointment, Allen said, “I’ve long been interested in Avivagen’s important positioning, have a meaningful shareholding and am pleased to be appointed to its Board of Directors. I believe Avivagen’s OxC-beta technology provides multiple business prospects that I may help it realize.”

   

Grant is experienced in corporate governance, capital markets, life sciences, and agriculture. She is a business law partner in Gowling Lafleur Henderson LLP. Grant has advised life sciences companies and is the Co-Director of York University’s Osgoode Hall Law School; she teaches corporate finance. Grant is “Very pleased to be appointed to Avivagen’s Board of Directors and look forward to using my skills to help ensure the success of the Company. I believe Avivagen has exciting opportunities with its products and intend to work hard to assist with realizing that potential.”

READ THE PRESS RELEASE

Avivagen Converting Liability to Equity and the Grant of Options

The life sciences company, Avivagen is converting liability to equity and a grant of options. A total of $20,999.95 CDN in debt will be converted to common shares. The 291,666 common shares will be priced at $0.072 CDN each. The liability is due to board fees owed to Mr. Amin Khalifa.

1,200,000 options were granted to board members as part of a remuneration package. The options were priced at $0.09 CDN per share. 

The conversion of debt to shares and option grants are both subject to approval of the TSX Venture Exchange.

About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol “VIV” and on OTC Pink as “CHEXF.” The Company’s goal is to develop and deliver scientifically-proven solutions that benefit companion and production animals by employing natural mechanisms for maintaining good health. Target markets include Livestock Productivity and Pet Wellness.

Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) – in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.

READ THE PRESS RELEASE

Avivagen Provides Update Regarding Proof of Concept Work On Permanent Non-Surgical Sterilization

Avivagen, a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, has provided an update on the proof of concept work with its optioned technology for the permanent sterilization of female mammals - targeted to eliminate the need for surgical spaying. 

READ MORE: Exploring the Non-Surgical Sterilization Conversation 

This technology is intended to be effective for companion animal sterilization, control of feral and wild animal populations and certain livestock applications. It is drug-based and does not used methods described in published literature. 

The proof of concept work did not demonstrate the intended sterilization effects. Avivagen and the inventor have analyzed the results and believe they may be due to issues with the drug actives, such as pharmacokinetic challenges. Avivagen has taken two actions to address this challenge to the project. 

"While we'd hoped to succeed in this recent proof-of-concept work, we continue to believe in this approach and will move forward with determining the path to a successful trial," said Cameron Groome, CEO and President of Avivagen. 

"We intend to update shareholders about our intentions with respect to this technology over the course of 2015." 

For more information, please visit www.avivagen.com 

Avivagen launches new corporate website

Avivagen Inc., a wellness company developing products that support and enhance the health and quality of life for animals and the people who care for them, announced today the launch of its new corporate website. 

Avivagen believes its new site reflects the evolution of the company into a more customer-focused entity. The website design is intended to enable stakeholders to more readily access corporate information, including the growing body of knowledge about the properties, functions and commercial utility of Avivagen's products - OxC-beta for livestock feeds and Vivamune™ Health Chews or Oximunol™ Chewables for pets. 

"As a business, we want to provide easy and full access to product information for all concerned parties," said Cameron Groome, Avivagen President and CEO. "We believe our new website will provide better access to all our data resources and we encourage you to visit."

For more information, visit www.avivagen.com

Exploring the Non-Surgical Sterilization conversation

Canadian wellness company Avivagen announced earlier this month it has entered into a one-year option to purchase an exclusive license for a permanent non-surgical pet sterilization technology from Dr. Duncan Hockley, director of the Veterinary Medical Centre of the University of Saskatchewan.

READ MORE: Avivagen Non-Surgical Sterilization

The invention is a novel and drug-based means of accomplishing this longstanding veterinary goal and could prove effective for urban animal sterilization and control of feral and wild animal populations. 

READ MORE: Avivagen Options Technology for Permanent and Non-Surgical Sterilization of Female Mammals

Animal overpopulation concerns in communities around the world are a regular topic at Urban Animal events as program delegates strive to find a humane, efficient, cost-effective and sustainable solution. 

If Avivagen's option is exercised, what timeline will follow with regard to traditional spay/neuter practices? How will non-surgical sterilization affect current spay/neuter programs? How will this method be funded and implemented on feral and stray populations? 

READ MORE: InfoStream - Non-Surgical Sterilization

As the 2014 Summit for Urban Animal Strategies draws near, stakeholders will undoubtedly be considering the opportunities and dilemmas arising from non-surgical sterilization procedures. Participants in the Urban Animal Forums on Friday (October 24, 2014) will be given the opportunity to join this conversation and other relevant and important conversations. 

REGISTER NOW to join the conversations! 

Avivagen Inc. is dedicated to developing science-based, natural health products for animals that are proven in clinical trials and offering veterinarians real alternatives to traditional treatments.

In consideration of the grant of the option on the technology, Avivagen has agreed to pay all application, maintenance and prosecution fees. Avivagen is also bearing the costs of proof-of-concept animal studies. 

Get the facts, have YourSAY, move the industry.